INTRODUCTION {#s1}
============

Due to lower fertility rates and advances in medical technology and services, the average age of the population is increasing worldwide. An aging society has a higher rate of various chronic diseases including abdominal obesity, type 2 diabetes, cardiac and cerebrovascular disease, and cancers[@r1],[@r2],[@r3],[@r4],[@r5]^)^. In particular, obesity is a primary factor in the etiology of diabetes mellitus (DM), hypertension, hyperlipidemia, and arthritis, and contributes to a reduced quality of life and shorter life expectancy[@r6]^)^. Obesity-induced blood lipid accumulation causes chronic inflammation and tissue damage, and induces insulin resistance and hyperinsulinemia; these stimulate excessive secretion of cholesterol by the liver, consequently triggering excessive secretion of bile, with subsequent increases in the size of the gallbladder and deterioration of gallbladder contractility[@r7], [@r8]^)^. It has been reported that reduction in gallbladder motility is associated with gallstones[@r9]^)^. The presence of gallstones is the most common disease of the biliary system. In Western countries, the prevalence of gallstones in females is 2 times greater than that in males, and in both genders, the prevalence increases with age; by the age of 70, the prevalence is approximately 30%[@r10]^)^. Abdominal ultrasonography is relatively cost-effective and is widely used for the diagnosis of gallstones. There is a high prevalence of asymptomatic gallstones. Gallstones are said to be closely associated with metabolic syndrome[@r11]^)^. To this end, we examined serologic factors associated with metabolic syndrome in relation to the occurrence of gallstones.

SUBJECTS AND METHODS {#s2}
====================

Subjects who visited a health promotion center in Seoul from March 2, 2013 to February 28, 2014 and had undergone abdominal ultrasonography were included in the study. All participants signed a written informed consent form approved by the Institutional Review Board of the Hallym University of Graduate Studies. Of a total of 428 subjects, 256 males and 172 females were selected at random and divided into 3 groups: those with a gallstone and concurrent metabolic syndrome during the study period, those with metabolic syndrome without a gallstone, and a normal group who did not have either a gallstone or metabolic syndrome. The diagnosis of metabolic syndrome was made when an individual met 3 or more of the following components of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) diagnostic criteria: (1) abdominal obesity (waist circumference ≥90 cm for Asian men or ≥80 cm for Asian women); (2) triglycerides ≥150 mg/dl; (3) HDL cholesterol ≤40 mg/dl for men or 50 mg/dl for women; (4) systolic/diastolic blood pressure ≥130/85 mmHg or receiving drug treatment; and (5) fasting plasma glucose ≥100 mg/dl[@r11]^)^. Subjects under 20 years of age or with factors that could affect metabolic syndrome such as insufficient data, or past surgical history involving the liver or biliary system were excluded. Height, weight, and blood pressure were measured using an Automatic Anthropometric Machine; the body mass index (BMI) was calculated according to \[Weight (kg)/Height (m^2^)\], and the degree of obesity was assessed according to \[(Current Weight (kg)/Standard Weight (kg) ×100 (%)\].Waist circumference was the smallest measurement taken with a tape measure at a point between the lowest rib and the iliac crest. Venous blood sampling was performed after a fast of at least 12 hours. The items measured included high-density lipoprotein (HDL) cholesterol, triglyceride, fasting blood glucose, total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), uric acid, total cholesterol, low-density lipoprotein (LDL) cholesterol, thyroid stimulating hormone (TSH), red blood cell (RBC) count, and white blood cell (WBC) count. Diagnosis of gallstones was made by 3 independent skilled medical radiology specialists using abdominal ultrasonography. Any migration of the echo with positional changes accompanied by shadowing toward the posterior of the gallbladder was diagnosed as having gallstones. Those with gallbladder diseases other than gallstones were excluded from the study. The numbers of gallstones were determined through imaging and interpretation of abdominal ultrasonography. When the number of stones was more than 10, the subject was considered to have 10 stones. The largest gallstones were measured using ultrasonic equipment (SSD-σ7; Aloka Company). Collected data were analyzed by using SPSS, version 18.0 for Windows (SPSS, Chicago, IL, USA). An independent t-test was conducted for correlations between the serum biochemical assay factors and occurrence of cholelithiasis in males and females with and without metabolic syndrome. Logistic regression analysis was performed to assess metabolic syndrome risk factors. Statistical significance was set at p\<0.05.

RESULTS {#s3}
=======

In male subjects, the mean age of those with metabolic syndrome was 43.59 ± 9.46 years and the mean BMI was 28.28 ± 3.02 kg/m^2^; these values were greater than in those without metabolic syndrome. In both males and females, those with metabolic syndrome had systolic and diastolic blood pressure (BP) higher than those without metabolic syndrome (p\<0.05) ([Table 1](#tbl_001){ref-type="table"}Table 1.General indicators of metabolic syndrome by genderGenderVariablePresence or absence of metabolic syndromeAverageGenderVariablePresence or absence of metabolic syndromeAverageMaleAgeNo40.9 ± 10.1FemaleAgeNo36.5 ± 10.2Yes43.5 ± 9.4Yes44.0 ± 9.5HeightNo173.6 ± 5.1HeightNo161.3 ± 5.8Yes172.9 ± 8.1Yes159.9 ± 5.3WeightNo69.5 ± 7.4WeightNo56.8 ± 8.7Yes85.2 ± 10.5Yes71.7 ± 10.2BMINo23.0 ± 2.4BMINo21.7 ± 2.9Yes28.2 ± 3.0Yes28.0 ± 3.7Degree of obesityNo104.9 ± 11.6Degree of obesityNo103.2 ± 14.2Yes129.2 ± 13.9Yes131.9 ± 20.9Waist circumferenceNo80.6 ± 6.4Waist circumferenceNo71.7 ± 7.0Yes95.1 ± 6.6Yes90.2 ± 9.2Systolic BPNo114.3 ± 10.6Systolic BPNo106.7 ± 10.9Yes126.3 ± 13.9Yes123.7 ± 13.2Diastolic BPNo72.0 ± 8.9Diastolic BPNo66.1 ± 7.8Yes80.2 ± 10.0Yes78.0 ± 9.7). In male subjects, those with metabolic syndrome showed the following: mean AST 31.5 ± 16 u/l, mean cholesterol 208.42 ± 54.89 mg/dl, mean fasting blood glucose 116.0 ± 3 mg/dl, mean RBC count 5.07 ± 0.3 × 10^3^/mm^3^, mean duration of smoking 14.6 ± 10 years, and mean maximum size of gallstones 1.35 ± 0.51 cm. All of the values represent significant differences from those of the group without metabolic syndrome (p\<0.05). In female subjects, those with metabolic syndrome showed the following: mean total bilirubin 0.66 ± 0.3 mg/dl, mean cholesterol 201.1 ± 32 mg/dl, mean HDL cholesterol 45.7 ± 9 mg/dl, and mean WBC count 6.5 ± 1.7 × 10^3^/mm^3^. All of the values represent significant differences from those of the group without metabolic syndrome (p\<0.05) ([Table 2](#tbl_002){ref-type="table"}Table 2.Serum biochemical indicators for metabolic syndrome by genderGenderVariablePresence or absence of metabolic syndromeAverageGenderVariablePresence or absence of metabolic syndromeAverageMaleTotal bilirubinNo0.95 ± 0.35FemaleTotal bilirubinNo0.78 ± 0.31Yes0.93 ± 0.39Yes0.66 ± 0.32Direct bilirubinNo0.29 ± 0.12Direct bilirubinNo0.22 ± 0.10Yes0.27 ± 0.12Yes0.20 ± 0.11Indirect bilirubinNo0.65 ± 0.24Indirect bilirubinNo0.56 ± 0.23Yes0.66 ± 0.28Yes0.46 ± 0.24ASTNo21.71 ± 15.94ASTNo20.81 ± 23.29Yes31.50 ± 16.61Yes28.76 ± 19.05ALTNo24.59 ± 25.65ALTNo18.72 ± 16.25Yes48.47 ± 34.86Yes38.00 ± 34.59ALPNo84.07 ± 47.99ALPNo73.13 ± 46.84Yes87.88 ± 49.51Yes105.50 ± 57.61Uric acidNo6.04 ± 1.20Uric acidNo4.35 ± 0.91Yes6.97 ± 3.58Yes5.27 ± 1.25CholesterolNo188.27 ± 30.21CholesterolNo183.26 ± 29.62Yes208.42 ± 54.89Yes201.16 ± 32.39HDL cholesterolNo58.03 ± 13.99HDL cholesterolNo66.15 ± 14.82Yes45.52 ± 10.76Yes45.70 ± 9.75LDL cholesterolNo109.54 ± 30.94LDL cholesterolNo100.15 ± 29.24Yes113.59 ± 35.29Yes113.94 ± 30.38TriglycerideNo106.47 ± 65.58TriglycerideNo89.39 ± 51.01Yes268.53 ± 235.74Yes242.78 ± 164.59FBSNo94.43 ± 9.33FBSNo89.42 ± 7.73Yes116.08 ± 35.98Yes119.50 ± 38.90TSHNo2.04 ± 1.05TSHNo2.46 ± 1.54Yes2.12 ± 1.27Yes2.25 ± 1.10RBC countNo4.90 ± 0.33RBC countNo4.41 ± 0.29Yes5.07 ± 0.36Yes4.59 ± 0.35WBC countNo5.82 ± 1.17WBC countNo5.86 ± 1.80Yes7.07 ± 1.71Yes6.54 ± 1.75AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, FBS: fasting blood sugar, TSH: thyroid stimulating hormone, RBC: red blood cells, WBC: white blood cells). In male subjects with metabolic syndrome, age was 1.029 times, weight was 1.205 times, HDL cholesterol was 0.922 times, triglyceride was 1.027 times, fasting blood glucose was 1.076 times, RBC count was 3.790 times, and WBC count was 1.824 times greater than in those without metabolic syndrome (p\<0.05) ([Table 3](#tbl_003){ref-type="table"}Table 3.Metabolic syndrome and binominal logistic regression model by item in menVariableBS.E.OR95%CIAge0.0280.0141.0291.001--1.057Height−0.0150.0190.9850.948--1.024Weight0.1860.0231.2051.152--1.260BMI0.8530.1082.3471.899--2.902Degree of obesity0.1850.0241.2031.149--1.260Waist circumference0.390.051.4771.340--1.628Systolic BP0.0790.0131.0821.055--1.110Diastolic BP0.0960.0171.11.064--1.137Total bilirubin−0.1310.3420.8770.449--1.715Direct bilirubin−1.5541.0340.2110.028--1.605Indirect bilirubin0.0540.4851.0560.408--2.733AST0.0840.0191.0871.048--1.128ALT0.0620.0111.0641.041--1.087ALP0.0020.0031.0020.996--1.007Uric acid0.3230.0971.3821.143--1.670Cholesterol0.0130.0041.0131.005--1.021HDL cholesterol−0.0820.0130.9220.899--0.945LDL cholesterol0.0040.0041.0040.996--1.011Triglyceride0.0270.0041.0271.020--1.035FBS0.0740.0141.0761.047--1.107TSH0.0620.1141.0640.850--1.331RBC count1.3320.3983.791.736--8.275WBC count0.6010.1111.8241.466--2.269Gallstones−0.7230.2670.4850.287--0.819Maximum size of gallstones0.7570.3552.1311.064--4.269Number of gall stones−0.0190.0530.9810.884--1.089AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, HDL: high density lipoprotein, LDL: low density lipoprotein, FBS: fasting blood sugar, TSH: thyroid stimulating hormone, RBC: red blood cells, WBC: white blood cells).

DISCUSSION {#s4}
==========

This study was conducted to investigate metabolic syndrome using 2005 American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria, and 2005 Abdominal Obesity Criteria published by the Korean Society for the Study of Obesity. The study also analyzed the association between biochemical factors and gallstones by gender, and the relative risks by factor for the presence of metabolic syndrome. In male subjects, metabolic syndrome was associated with age, weight, BMI, degree of obesity, waist circumference, systolic BP, diastolic BP, AST, ALT, uric acid, total cholesterol, HDL cholesterol, triglycerides, fasting blood glucose, RBC count, WBC count, presence of gallstones, and the size of gallstones. In female subjects, metabolic syndrome was associated with age, weight, BMI, degree of obesity, waist circumference, systolic BP, diastolic BP, total bilirubin, indirect bilirubin, AST, ALT, ALP, uric acid, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, fasting blood glucose, RBC count, and WBC count. In men, there were relatively more subjects with metabolic syndrome within each generation in their 30s, 40s, and 50s. In women, there were more subjects without metabolic syndrome within each generation in their 30s and 40s. These results are different from those reported by Son et al., who concluded that the reduction in male hormones in men and reduction of female hormones in menopausal women were associated with increased prevalence of metabolic syndrome with aging, in both men and women[@r12]^)^. Park et al. reported that the lower the rate of obesity, weight, and BMI, the higher the concentration of adiponectin; they stated that adiponectin acted as a critical element in the development of insulin resistance, and that this information would be helpful for the treatment of diabetes[@r13]^)^. Similarly, this study found that factors such as weight, BMI, and the degree of obesity were significantly greater in those with metabolic syndrome. In men, total, direct, and indirect bilirubin showed no statistical association with metabolic syndrome. However, in women with metabolic syndrome, total bilirubin was 0.66 ± 0.32 mg/dl and indirect bilirubin was 0.46 ± 0.24 mg/dl, whereas in women without metabolic syndrome, total bilirubin was 0.78 ± 0.31 mg/dl and indirect bilirubin was 0.56 ± 0.23 mg/dl, indicating a significant inverse reduction. These outcomes were consistent with a report by Jo et al. that indicated that total, direct, and indirect bilirubin were inversely associated with metabolic syndrome[@r14]^)^. Choi et al. also reported that total bilirubin was inversely associated with metabolic syndrome[@r15]^)^, while Guzek et al. reported that bilirubin was inversely associated with metabolic syndrome, and affected antioxidation and inflammation[@r16]^)^. There have been reports that AST, ALT, and ALP all reflected the degree of inflammation, and were associated with diabetes, impaired glucose tolerance, and metabolic syndrome[@r17]^)^. In this study as well, AST and ALT were related to metabolic syndrome in both men and women. However, ALP was related to metabolic syndrome only in women; previous studies reported that this was because ALP is an osteogenic indicator in pre- and postmenopausal women, and is correlated with triglycerides and LDL cholesterol[@r18]^)^. Such differences are expected, given the different physical developmental characteristics of men and women, and might also be due to the differences in age distributions within each study group. In particular, the RBC counts were found to have with substantially.
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